



Pre - PA Allowance

None

Prior-Approval Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Unresectable or metastatic melanoma
2. Cutaneous melanoma (Stage III)
 - a. Used as adjuvant therapy
 - b. Pathologic involvement of regional lymph nodes of more than 1 mm
 - c. Patient has undergone complete resection, including total lymphadenectomy
3. Central nervous system (CNS) metastases
 - a. Yervoy was active against the primary tumor (melanoma)
 - b. Patient has recurrent disease
4. Small cell lung cancer (SCLC)
 - a. Used in combination with nivolumab
5. Unresectable malignant pleural mesothelioma
 - a. Used as first-line treatment in combination with nivolumab
6. Advanced renal cell carcinoma
 - a. Patient is considered to have an intermediate or poor prognosis
 - b. Used as first-line treatment in combination with nivolumab
7. Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
 - a. Diagnosis confirmed by PCR-based assay genetic testing
 - b. Used in combination with nivolumab
8. Unresectable or metastatic hepatocellular carcinoma (HCC)



**YERVOY
(ipilimumab)**

- a. Used as first-line treatment **OR** patient has had prior treatment with sorafenib
 - b. Used in combination with nivolumab
- 9. Unresectable advanced or metastatic esophageal squamous cell carcinoma
 - a. Tumors express PD-L1 as determined by an FDA-approved test
 - b. Used as first-line treatment in combination with nivolumab
- 10. Metastatic non-small cell lung cancer (NSCLC)
 - a. **NO** EGFR or ALK genomic tumor aberrations with **ONE** of the following:
 - i. Tumors express PD-L1 as determined by an FDA-approved test **AND** used as first-line treatment in combination with nivolumab
 - ii. Used as first-line treatment in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy
- 11. Recurrent non-small cell lung cancer (NSCLC)
 - a. **NO** EGFR or ALK genomic tumor aberrations
 - b. Used as first-line treatment in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy

AND ALL of the following:

- 1. Clinical chemistries, including adrenocorticotrophic hormone (ACTH) level, and liver and thyroid function tests are evaluated at baseline and before each dose
- 2. Agree to permanently discontinue Yervoy and initiate corticosteroid therapy for severe immune-mediated reactions
- 3. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Yervoy and for 3 months after the last dose

Prior - Approval Limits

Duration 6 months



Prior – Approval *Renewal* Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Cutaneous melanoma (Stage III)
2. Central nervous system (CNS) metastases
3. Small cell lung cancer (SCLC)
 - a. Used in combination with nivolumab
4. Unresectable malignant pleural mesothelioma
 - a. Used in combination with nivolumab
5. Unresectable advanced or metastatic esophageal squamous cell carcinoma
 - a. Used in combination with nivolumab
6. Metastatic or recurrent non-small cell lung cancer (NSCLC)
 - a. Used in combination with nivolumab

AND ALL of the following:

1. **NO** disease progression or unacceptable toxicity
2. Clinical chemistries, including adrenocorticotrophic hormone (ACTH) level, and liver and thyroid function tests are evaluated before each dose
3. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Yervoy and for 3 months after the last dose

Prior – Approval *Renewal* Limits

Duration 18 months

TWO renewals **ONLY** for Adjuvant Treatment of Melanoma

ONE renewal **ONLY** for Esophageal Squamous Cell Carcinoma, NSCLC, or Malignant Pleural Mesothelioma



**BlueCross.
BlueShield.**

Federal Employee Program.

**YERVOY
(ipilimumab)**

NO renewal for Unresectable or Metastatic Melanoma, Renal Cell Carcinoma, Colorectal Cancer, or Hepatocellular Carcinoma